Alyeska Investment Group L.P. Acquires 95,664 Shares of Celcuity, Inc. $CELC

Key Points

• Alyeska Investment Group increased its Celcuity stake by 127.2% in the second quarter, adding 95,664 shares for a total of 170,846 shares valued at approximately $17.9 million. Institutional investors collectively own 63.33% of the company.
• Analysts remain broadly positive, with 10 Buy ratings and one Sell rating and a consensus price target of $154.55. However, recent price targets were mixed, ranging from $150 to $175.
• Celcuity reported a quarterly loss of $1.44 per share, missing the $1.16 consensus estimate. The clinical-stage biotechnology company develops precision-oncology diagnostic assays to help identify effective targeted cancer treatments.

Alyeska Investment Group L.P. boosted its holdings in Celcuity, Inc. (NASDAQ:CELC - Free Report) by 127.2% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 170,846 shares of the company's stock after purchasing an additional 95,664 shares during the quarter. Alyeska Investment Group L.P. owned about 0.35% of Celcuity worth $17,874,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in CELC. NEA Management Company LLC boosted its position in shares of Celcuity by 64.9% in the 4th quarter. NEA Management Company LLC now owns 3,535,561 shares of the company's stock worth $352,637,000 after purchasing an additional 1,391,300 shares in the last quarter. Avoro Capital Advisors LLC bought a new position in Celcuity during the 4th quarter valued at approximately $310,302,000. Soleus Capital Management L.P. raised its stake in Celcuity by 17.0% during the second quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company's stock valued at $40,208,000 after buying an additional 437,696 shares during the last quarter. Vanguard Group Inc. raised its stake in Celcuity by 10.7% during the fourth quarter. Vanguard Group Inc. now owns 2,279,433 shares of the company's stock valued at $227,351,000 after buying an additional 220,386 shares during the last quarter. Finally, State Street Corp boosted its holdings in Celcuity by 126.6% in the fourth quarter. State Street Corp now owns 1,637,687 shares of the company's stock worth $163,343,000 after acquiring an additional 914,887 shares in the last quarter. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Weiss Ratings upgraded Celcuity from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, June 4th. Guggenheim upped their price target on shares of Celcuity from $165.00 to $175.00 and gave the stock a "buy" rating in a research note on Monday, August 17th. Stifel Nicolaus cut their price objective on shares of Celcuity from $175.00 to $150.00 and set a "buy" rating on the stock in a research report on Friday, August 14th. Wells Fargo & Company reduced their price objective on shares of Celcuity from $183.00 to $166.00 and set an "overweight" rating for the company in a research note on Wednesday, June 3rd. Finally, Wall Street Zen cut shares of Celcuity from a "sell" rating to a "strong sell" rating in a report on Saturday, August 15th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Celcuity has an average rating of "Moderate Buy" and a consensus price target of $154.55.

Celcuity Price Performance

NASDAQ CELC opened at $89.06 on Tuesday. Celcuity, Inc. has a one year low of $44.42 and a one year high of $151.02. The stock has a 50-day moving average of $94.62 and a 200 day moving average of $107.04. The company has a debt-to-equity ratio of 6.04, a quick ratio of 8.93 and a current ratio of 8.93. The company has a market capitalization of $4.36 billion, a price-to-earnings ratio of -20.71 and a beta of 0.21.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.28). On average, sell-side analysts forecast that Celcuity, Inc. will post -4.75 EPS for the current year.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

Want to see what other hedge funds are holding CELC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celcuity, Inc. (NASDAQ:CELC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source